论文部分内容阅读
目的:探讨参附注射液治疗心力衰竭的疗效及对高敏C反应蛋白(hs-CRP)水平的影响。方法:选取2016年1月—2017年1月喀什地区第一人民医院收治的心力衰竭患者94例作为研究对象,以随机数字表法分为观察组和对照组,每组47例。两组患者均给予抗心力衰竭常规基础治疗,在此基础上,观察组患者加用参附注射液治疗。观察两组患者的临床疗效,心功能指标及血清hs-CRP水平变化情况。结果:观察组患者的总有效率为89.36%(42/47),明显高于对照组的70.21%(33/47),差异有统计学意义(P<0.05)。治疗后,两组患者左心室射血分数明显高于治疗前,且观察组患者明显高于对照组;两组患者左心室舒张末内径、左心室收缩末内径明显低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05);观察组患者血清hsCRP水平明显低于本组治疗前及对照组治疗后,差异均有统计学意义(P<0.05)。结论:参附注射液治疗心力衰竭的疗效较好,可改善患者心功能,减轻炎症反应。
Objective: To investigate the curative effect of Shenfu injection on heart failure and its effect on the level of hs-CRP. Methods: 94 patients with heart failure admitted to the First People’s Hospital of Kashgar from January 2016 to January 2017 were selected as study subjects, and randomly divided into observation group and control group with 47 cases in each group. Two groups of patients were given routine anti-heart failure basic treatment, on this basis, the observation group plus Shenfu injection. The clinical efficacy, cardiac function and serum hs-CRP level in two groups were observed. Results: The total effective rate in the observation group was 89.36% (42/47), which was significantly higher than that in the control group (70.21%, 33/47). The difference was statistically significant (P <0.05). After treatment, left ventricular ejection fraction was significantly higher in both groups than before treatment, and the observation group was significantly higher than the control group; left ventricular end-diastolic diameter, left ventricular end-systolic diameter was significantly lower than before treatment in both groups, and the observation group (P <0.05). The serum hsCRP level in the observation group was significantly lower than that in the control group before and after treatment (P <0.05). Conclusion: Shenfu injection is effective in treating heart failure and can improve cardiac function and reduce inflammation.